Healthcare Industry News: S.A.
News Release - November 18, 2016
Apricus Biosciences Provides Update on Vitaros NDA Following Receipt of FDA Feedback
SAN DIEGO, Nov. 18, 2016 -- (Healthcare Sales & Marketing Network) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has received feedback in response to its previously announced Type B Meeting request to the U.S. Food and Drug Administration (FDA). The purpose of the FDA meeting request was to confirm Apricus’ strategy for addressing the deficiencies contained in the 2008 Complete Response letter. Based upon our expert panel’s review of the FDA’s feedback, and the available Vitaros clinical and non-clinical data used to obtain regulatory approvals outside of the U.S., the Company believes that there iS.A.viable regulatory pathway for resubmission of the Vitaros NDA in the U.S. and, as such, we intend to re-submit the NDA as soon as possible in 2017.Specifically, the FDA provided clarity on the requirements needed to address the deficiencies in the 2008 Complete Response letter to include suggested additional analysis of existing clinical and non-clinical data. The FDA feedback did not indicate that new clinical studies would be required for re-submission. Importantly, the FDA determined that Vitaros, under current regulations, is now considered a drug-device combination and, as such, Apricus waS.A.vised to meet with the Office of Product Quality to confirm the neceS.A.y device engineering and compliance requirements for the NDA re-submission.
“We are encouraged by the FDA’s constructive feedback regarding the Vitaros NDA re-submission strategy and we appreciate their valuable input, which we believe will help to further strengthen our re-submission,” said Richard Pascoe, Chief Executive Officer of Apricus. “Importantly, we believe that we can adequately address the DDAIP safety and partner transference risk noted in the 2008 Complete Response letter and we can further strengthen our clinical benefit section in the planned re-submission, using a methodology provided to us by the FDA. However, given the determination by the FDA that Vitaros is now a drug-device combination, we will need to meet with the Office of Product Quality to clarify any additional conditions that may be required for approvability, which will likely delay our re-submission until the second half of 2017.”
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) iS.A.biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus’ commercial product, Vitaros®, for the treatment of erectile dysfunction, iS.A.proved in Canada and certain countries in Europe, Latin America and the Middle East and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Recordati Ireland Ltd. (Recordati), Ferring International Center S.A. (Ferring Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one active product candidate, RayVa™, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon.
For further information on Apricus, visit http://www.apricusbio.com.
*Vitaros® iS.A.registered trademark of NexMed International Limited. Such trademark is registered in certain countries throughout the world and pending registration in the United S.A.es.
Forward-Looking S.A.ements
This press release contains forward-looking S.A.ements within the meaning of the Private Securities Litigation Reform Act, aS.A.ended. S.A.ements in this press release that are not purely historical are forward-looking S.A.ements. Such forward-looking S.A.ements include, among other things: references to the need for additional clinical or pre-clinical data prior to the re-submission of the Vitaros NDA and the FDA’s view on such a need; the timing of the re-submission of the Vitaros NDA, including the need to address the issues raised by the FDA’s feedback or any issues raised by the Office of Product Quality related to the FDA’s determination that Vitaros is now a drug-device combination; and Apricus’ ability to address the clinical and non-clinical data deficiencieS.A.d other deficiencies noted in the 2008 Complete Response letter. Actual results could differ from those projected in any forward-looking S.A.ements due to a variety of reasons that are outside of Apricus’ control, including, but not limited to: the FDA, including the Office of Product Quality, requiring additional clinical and pre-clinical data prior to the Vitaros NDA re-submission; Apricus’ ability to addresS.A.y conditions for approvability raised by the FDA’s Office of Product Quality; the risks of any additional adverse safety or other data arising from the saleS.A.d use of Vitaros in certain countries in Europe and elsewhere; Apricus’ financial position and need for additional capital to fund its operations through the NDA re-submission and the FDA’s review of the NDA, which may be adversely impacted if Apricus is unable to maintain the continued listing of its common stock on the NaS.A. stock market; and other risks identified by Apricus in its reports filed with the SecuritieS.A.d Exchange Commission (SEC). These forward-looking S.A.ementS.A.e made as of the date of this press release, and ApricuS.A.sumes no obligation to update the forward-looking S.A.ements, or to update the reasons why actual results could differ from those projected in the forward-looking S.A.ements. ReaderS.A.e urged to read the risk factors set forth in Apricus’ most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reportS.A.e available from the SEC's website at www.sec.gov or without charge from Apricus.
Source: Apricus Biosciences
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!